AZRX - AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients

Thinly traded nano cap AzurRx BioPharma (AZRX) perks up 9% premarket on light volume in reaction to the commencement of dosing in Turkey in an open-label Phase 2 clinical trial evaluating MS1819, combined with standard-of-care [porcine -derived pancreatic enzyme replacement therapy ((PERT))], for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis ((CF)).MS1819 is a recombinant lipase (one of the three main pancreatic enzymes) derived from the yeast Yarrowia Lipolytica. Together with PERT, it is designed to enable CF patients to eat a normal-to-high fat diet while avoiding unwanted GI symptoms.

For further details see:

AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients